Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by Kuopio University Hospital
Sponsor:
Information provided by (Responsible Party):
Sari Hamalainen, Kuopio University Hospital
ClinicalTrials.gov Identifier:
NCT00781040
First received: October 27, 2008
Last updated: April 19, 2016
Last verified: April 2016

October 27, 2008
April 19, 2016
December 2006
December 2016   (final data collection date for primary outcome measure)
This study evaluates epidemiology, microbiology and outcome of neutropenic fever and severe sepsis in haematological patients with special reference to the kinetics of inflammatory markers. [ Time Frame: Within neutropenic period after treatment ] [ Designated as safety issue: No ]
This study evaluated epidemiology, microbiology and outcome of neutropenic fever and severe sepsis in haematological patients with special reference to the kinetics of specific inflammatory markers.
Not Provided
Complete list of historical versions of study NCT00781040 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients
Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients
The aim of this study is to find out whether inflammation markers including cardiac markers have predictive value in evaluation of pathogenesis of sepsis in neutropenic haematological patients.
Adult AML and ASCT patients with neutropenic fever. Observation of possible progress to severe sepsis or septic shock. Blood sample collection on days 0-3 (from the beginning of neutropenic fever).
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Neutropenic patients in haematology ward having neutropenic fever with or without severe sepsis
Sepsis
Other: Severe sepsis vs. non-severe sepsis
To compare these two groups
Other Names:
  • Severe sepsis vs. non-severe sepsis adult AML patients
  • Severe sepsis vs. non-severe sepsis adult ASCT patients
Neutropenic patients
Adult AML and ASCT patients with neutropenic fever.
Intervention: Other: Severe sepsis vs. non-severe sepsis
Vänskä M, Koivula I, Hämäläinen S, Pulkki K, Nousiainen T, Jantunen E, Juutilainen A. High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients. Haematologica. 2011 Sep;96(9):1385-9. doi: 10.3324/haematol.2011.044925.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
270
December 2016
December 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • diagnosis: acute myeloid leukaemia
  • age under 70 years
  • neutropenic fever

Exclusion Criteria:

  • age above 70 years
  • no neutropenic fever
Both
18 Years to 70 Years   (Adult, Senior)
No
Contact: Esa Jantunen, M.D, PhD +35817173311 esa.jantunen@kuh.fi
Contact: Sari Hämäläinen, M.D, PhD +35817173311 sari.hamalainen@kuh.fi
Finland
 
NCT00781040
KUH5101409
No
No
Not Provided
Sari Hamalainen, Kuopio University Hospital
Kuopio University Hospital
Not Provided
Study Director: Esa Jantunen, M.D, PhD Kuopio University Hospital
Kuopio University Hospital
April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP